Profile Details

Create Project

★★★★★

☆☆☆☆☆

★★★★★

☆☆☆☆☆

Hire Dr. Luca S.

Canada

Freelance Computational Drug Discovery Scientist (small molecules/biologics) | Intelligence scouting on AI applications

Profile Summary

I bring a 360° approach to the table thanks to the experience and expertise gained in 13+ years, of which 4+ in Pharmaceutical Industry and 9 years in Academia. A Pharmaceutical Biotechnologist by training during my BSc, I then continued with my MSc in Molecular Medicine and a PhD, which combined biochemistry techniques with computational methods to guide and support the experimental part. I was then a guest scientist at the University of Innsbruck (Computer-Aided Molecular Design Group), where I completed 2 projects in less than 3 months. My contribution resulted in a 10% in vitro hit rate for the identification of endocrine disruptors, and in an all-atom model of a transmembrane protein which could be then used for further structure-based drug discovery campaigns. I also mentored students in protein modeling and molecular dynamics simulations. I then joined a Pharmaceutical company, where I: Developed a novel computational chemistry/cheminformatics approach within the first 4 months of appointment, opening new opportunities for the company || Applied AI-based technology and CADD tools towards small-molecule drug discovery for rare diseases || Obtained a 20% in vitro hit rate on a CNS target within the first 2 months of appointment || Successfully identified 18 active compounds for 2 additional non-CNS projects || Won a prestigious industrial grant (> 100k €) for the development of high-tech industrial R&D projects

Subject Matter Expertise

• ★ Molecular Modeling
• ★ Molecular Docking
• ★ Structural Bioinformatics
• ☆ Chemoinformatics
• ☆ Computational Biology
• ☆ Biochemistry
• ☆ Biochemical Assays
• ☆ Binding Assays
• ☆ Molecular Biology
• ☆ Genetics
• ☆ PCR
• ☆ Molecular Cloning
• ☆ Mutagenesis
• ☆ Plasmid DNA
• ☆ ChIP-Seq
• ☆ Cell Biology
• ☆ Stem Cell Research
• ☆ Biotechnology & Bioengineering
• ☆ Recombinant Protein Expression
• ☆ Fluorescence Microscopy
• ☆ Scanning Probe Microscopy
• ☆ Bioinformatics
• ☆ Cell Culture

Services

• Writing
• Research
• Consulting
• Data & AI

Writing Technical Writing

Research Market Research, User Research, Gap Analysis, Gray Literature Search, Systematic Literature Review

Consulting Scientific and Technical Consulting

Data & AI Statistical Analysis, Data Visualization, Data Processing

Work Experience

Consultant/Owner

Luca Signorile

January 2021 - Present

Senior Computational Chemist

SOM Biotech

May 2018 - December 2020

Postdoctoral guest scientist

Universität Innsbruck

March 2018 - May 2018

Doctoral Candidate

Erasmus MC

March 2013 - September 2017

Education

PhD

Erasmus University Rotterdam

March 2013 - September 2017

MSc

Erasmus Medical Center

September 2010 - September 2012

BSc

Università degli Studi di Bari

September 2006 - March 2010

Certifications

• Certification details not provided.

Publications

JOURNAL ARTICLE

Jo S, Signorile L, Kim S, Kim MS, Huertas O, Insa R, Reig N, Shin DH(2022). A Study of Drug Repurposing to Identify SARS-CoV-2 Main Protease (3CLpro) Inhibitors . International journal of molecular sciences.

Yu N, Signorile L, Basu S, Ottema S, Lebbink JHG, Leslie K, Smal I, Dekkers D, Demmers J, Galjart N(2016). Isolation of Functional Tubulin Dimers and of Tubulin-Associated Proteins from Mammalian Cells . Current biology : CB.

Halim D, Hofstra RM, Signorile L, Verdijk RM, van der Werf CS, Sribudiani Y, Brouwer RW, van IJcken WF, Dahl N, Verheij JB, et al.(2015). ACTG2 variants impair actin polymerization in sporadic Megacystis Microcolon Intestinal Hypoperistalsis Syndrome . Human molecular genetics.

Engelen E, Brandsma JH, Moen MJ, Signorile L, Dekkers DH, Demmers J, Kockx CE, Ozgür Z, van IJcken WF, van den Berg DL, et al.(2015). Proteins that bind regulatory regions identified by histone modification chromatin immunoprecipitations and mass spectrometry . Nature communications.

Narcisi R, Signorile L, Verhaar JA, Giannoni P, van Osch GJ(2012). TGFβ inhibition during expansion phase increases the chondrogenic re-differentiation capacity of human articular chondrocytes . Osteoarthritis and cartilage.